Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals

Clin Microbiol Infect. 2004 May;10(5):448-51. doi: 10.1111/j.1469-0691.2004.00830.x.

Abstract

Clinical isolates of methicillin-resistant Staphylococcus aureus (n = 1070) collected from 63 French general hospitals during June 2000 (n = 1070) were screened initially for reduced susceptibility to glycopeptides (GISA) on brain-heart infusion agar containing teicoplanin 6 mg/L. Glycopeptide MICs were determined for the 145 isolates that grew on the screening plates. Of the 1070 isolates, 1.4% were GISA on Mueller-Hinton agar, and 2.9% by Etest with a high inoculum, while 0.7% and 2.9% were GISA by vancomycin and teicoplanin population analysis profiles, respectively. Most isolates were resistant to gentamicin and rifampicin or fosfomycin or fusidic acid, as determined by disk diffusion. Pulsed-field gel electrophoresis of the 31 GISA isolates identified four clones, with dissemination of one predominant clone. In these French hospitals there was a low incidence of GISA and hetero-GISA.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Bacterial
  • Electrophoresis, Gel, Pulsed-Field
  • France / epidemiology
  • Humans
  • Methicillin Resistance*
  • Microbial Sensitivity Tests
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / epidemiology
  • Staphylococcal Infections / microbiology*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / isolation & purification
  • Teicoplanin / pharmacology
  • Teicoplanin / therapeutic use
  • Vancomycin / pharmacology
  • Vancomycin / therapeutic use
  • Vancomycin Resistance

Substances

  • Anti-Bacterial Agents
  • Teicoplanin
  • Vancomycin